Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis

Manuel Rubio-Rivas, Jose María Mora-Luján, Abelardo Montero, Narcís A. Homs, Jordi Rello, Xavier Corbella
doi: https://doi.org/10.1101/2020.09.05.20188912

Article usage

Article usage: September 2020 to September 2024

AbstractFullPdf
Sep 202013530407
Oct 20203420134
Nov 2020247051
Dec 2020115039
Jan 202193026
Feb 2021152421
Mar 20211602730
Apr 2021155211
May 2021117519
Jun 202190511
Jul 2021104831
Aug 2021641827
Sep 2021121223
Oct 2021120436
Nov 202177434
Dec 202149110
Jan 202243713
Feb 20222526
Mar 202227211
Apr 202230115
May 202218219
Jun 20221737
Jul 20221405
Aug 202226610
Sep 202226217
Oct 202221115
Nov 20221808
Dec 202224310
Jan 202374511
Feb 202324814
Mar 202321113
Apr 202382117
May 202318219
Jun 202311417
Jul 20231605
Aug 2023191216
Sep 202318611
Oct 20231016
Nov 202336253
Dec 20231935
Jan 202412514
Feb 202414311
Mar 202411313
Apr 2024856
May 20241416
Jun 2024452019
Jul 202413110
Aug 202425613
Sep 202426812
Back to top
Posted September 26, 2020.
Download PDF
Data/Code
Email
Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis
Manuel Rubio-Rivas, Jose María Mora-Luján, Abelardo Montero, Narcís A. Homs, Jordi Rello, Xavier Corbella
medRxiv 2020.09.05.20188912; doi: https://doi.org/10.1101/2020.09.05.20188912
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area